Raymond James Financial
RPTX

Raymond James Financial’s Repare Therapeutics RPTX Stock Holding History

Raymond James Financial’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-230
Closed -$320 – 6399
2025
Q2 		$320 Buy
+230
New +$300 ﹤0.01% 6733

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return

Raymond James Financial's RPTX Position: Q3 2025 in Review

Raymond James Financial sold out of Repare Therapeutics (RPTX) in Q3 2025, closing a stake of 230 shares — an estimated $320 sold.

Raymond James Financial first reported a position in RPTX in Q2 2025 and held it in 1 quarter. The position peaked at $320 in Q2 2025. 45 funds tracked by Wall St. Rank hold RPTX as of Q3 2025.

  • Raymond James Financial reported no remaining Repare Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 230 Repare Therapeutics shares in Q3 2025, an estimated $320.
  • Raymond James Financial first reported a position in Repare Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Repare Therapeutics position peaked at $320 in Q2 2025.
  • 45 funds tracked by Wall St. Rank held Repare Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.